IP Library Granted Patent US 7,589,237
Granted Patent B2
US 7,589,237 · App. 12/173,626 · Granted Sep 15, 2009

Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine

Assignee: Sepracor Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,589,237
App. No.
12/173,626
Granted
Sep 15, 2009
Kind
B2
Abstract

Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Claims (10)

1. A method for treating cerebral function disorders, the method comprising administering to a person in need of treatment for a cerebral function disorder a therapeutically effective amount of a compound of formula PQ:

or a salt thereof.

2. A method according to claim 1 , wherein the compound of formula PQ is selected from formula P or Q:

or a salt thereof.

3. A method according to claim 1 , wherein the compound of formula PQ is (1S,4R)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine or a salt thereof.

4. A method according to claim 1 , wherein the compound of formula PQ is (1R,4S)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine or a salt thereof.

5. A method according to claim 1 , wherein the compound of formula PQ is (1S,4R)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride.

6. A method according to claim 1 , wherein the compound of formula PQ is (1R,4S)—N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine hydrochloride.

7. A method according to claim 1 , wherein the cerebral function disorder is Alzheimer's type dementia.

8. A method according to claim 1 , wherein the cerebral function disorder is Parkinson's disease.

Assignments (1)
CHANGE OF NAME Recorded Jan 26, 2011
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025699/0042 →
Continuity (7)
Continuation 1141658600 · May 3, 2006
Continuation 1133819100 · Jan 24, 2006
Continuation 1122089100 · Sep 7, 2005
Continuation 1066317300 · Sep 16, 2003
Provisional Application 6041130400 · Sep 16, 2002
Provisional Application 6041130500 · Sep 16, 2002
Related Publication 20080280993A1 · Nov 13, 2008